Answers are grounded in this paper and cite their sources.
Phase 2 trial demonstrates reduced HDV RNA and ALT in Hepatitis D patients, suggesting tobevibart with elebsiran is effective.
In this phase 2 trial, tobevibart plus elebsiran as well as tobevibart monotherapy decreased HDV RNA and ALT levels through week 48. Treatment with tobevibart plus elebsiran was associated with a high incidence of undetectable HDV RNA and of a decrease in the HBsAg level. (Funded by Vir Biotechnology; ClinicalTrials.gov number, NCT05461170.).
No takes yet. Share an insight, caveat, or question.
Asselah et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: